Posted May 19, 2017
Almost a third of drugs cleared by the Food and Drug Administration pose safety risks that are identified only after their approval, according to a study published Tuesday. The researchers said the study, which appeared in JAMA, shows the need for ongoing monitoring of new treatments years after they hit the market. Read more.